-
公开(公告)号:NO996045A
公开(公告)日:1999-12-08
申请号:NO996045
申请日:1999-12-08
Applicant: BASF AG
Inventor: STEINER GERD , DULLWEBER UTA , STARCK DOROTHEA , BACH ALFRED , WICKE KARSTEN , TESCHENDORF HANS-JUERGEN , GARCIA-LADONA FRANCISCO-JAVIER , EMLING FRANZ
IPC: A61K31/519 , A61P25/00 , A61P25/24 , A61P43/00 , C07D495/14 , A61K31/505 , C07D221/00 , C07D239/00 , C07D333/00
CPC classification number: C07D495/14
-
公开(公告)号:DK0772604T3
公开(公告)日:1999-11-01
申请号:DK95926895
申请日:1995-07-14
Applicant: BASF AG
Inventor: HELLENDAHL BEATE , LANSKY ANNEGRET , MUNSCHAUER RAINER , BIALOJAN SIEGFRIED , UNGER LILIANE , TESCHENDORF HANS-JUERGEN , WICKE KARSTEN , DRESCHER KARLA
IPC: C07D249/08 , A61K31/41 , A61K31/435 , A61K31/4427 , A61K31/445 , A61K31/505 , A61K31/53 , A61P1/08 , A61P25/18 , A61P25/20 , A61P25/24 , A61P25/26 , C07D249/12 , C07D249/14 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14
Abstract: PCT No. PCT/EP95/02781 Sec. 371 Date Jan. 14, 1997 Sec. 102(e) Date Jan. 14, 1997 PCT Filed Jul. 14, 1995 PCT Pub. No. WO96/02520 PCT Pub. Date Feb. 1, 1996The present invention relates to triazole compounds of the following formula: where R1, R2, A, B and Ar have the meanings stated in the description. The compounds according to the invention have a high affinity for the dopamine D3 receptor and can therefore be used to treat disorders which respond to dopamine D3 ligands.
-
23.
公开(公告)号:BG103122A
公开(公告)日:1999-09-30
申请号:BG10312299
申请日:1999-01-27
Applicant: BASF AG
Inventor: STEINER GERD , LUBISCH WILFRIED , BACH ALFRED , EMLING FRANZ , WICKE KARSTEN , TESCHENDORF HANS-JURGEN , BEHL BERTHOLD , KERRIGAN FRANK , CHEETHAM SHARON
IPC: A61K31/435 , A61K31/519 , A61P25/24 , A61P43/00 , C07D211/00 , C07D239/00 , C07D333/00 , C07D495/14
Abstract: The 3-substituted 3,4,5,6,7.8-hexahydro-pyrido[4', 3':4,5]-thieno [2,3-d] pyrimidine derivatives can be used asmedicamentous forms for diseases where there is redud serotoninconcentration and where, within the therapy, the activity of thepresnaptic receptors 5-HT1B-, 5-HT1A-, 5-HT1D-, should be blockedwithout seriously affecting any other receptors. Depression is anexample for such morbid state. The compounds have formulain which R1 is hydrogen, C1-C4-alkyl group, acetyl, benzoyl,phenylalkyl-C1-C4-residue where the aromatic residue is optionallysubstituted with halogen, C1-C4-alkyl, trifluoromethyl, hydroxy-,C1-C4-alkoxy-, amino-, cyano- or nitrogroups or isnaphtalene-C1-C4-alkyl residue, phenylalkanon-C2-C4-residue orphenylcarbamoylalkyl-C2-residue where the phenyl group can besubstituted by halogen; R2 optionally is mono-, di- ortrisubstituted with halogen atoms, C1-C4-alkyl, trifluoromethyl,trifluormethoxy, hydroxy, C1-C4-alkoxy, amino-, monomethylamino-,diethylamino-, cyano- or nitrogroup, phenyl, pyridyl, pyrimidinylor pyrasinyl reside which can optionally be ringed by one benzenering which optionally can be mono- or disubstituted with halogenatom, C1-C4-alkyl, hydroxy, trifluormethyl, C1-C4-alkoxy, amino-,cyano- or nitrogroup, and optionally can contain one nitrogen atomor be ringed by 5- or 6-member ring which can contain one to twooxygen atoms, or can be substituted by phenyl-C1-C2-alkyl, oralkoxygroup, respectively, where the phenyl residue can besubstituted with halogen, methyl, trifluormethyl or methoxygroup.A is NH or oxygen, B is hydrogen or methyl, C is hydrogen, methylor hydroxy, X is nitrogen atom, Y is the group CH2, CH2- CH2,CH2-CH2-CH2 or CH2-CH, Z is nitrogen atom, carbon or CH where thebond between Y and Z can be double, n has the value of 2, 3 or 4.The invention also relates to physiologically acceptable salts ofthe above compounds.6 claims
-
公开(公告)号:BR9711724A
公开(公告)日:1999-08-24
申请号:BR9711724
申请日:1997-08-22
Applicant: BASF AG
Inventor: STEINER GERD , LUBISCH WILFRIED , BACH ALFRED , EMLING FRANZ , WICKE KARSTEN , TESCHENDORF HANS JURGEN , BEHL BERTHOLD , CHEETHAM SHARON , KERRIGAN FRANK
IPC: A61K31/435 , A61K31/519 , A61P25/24 , A61P43/00 , C07D211/00 , C07D239/00 , C07D333/00 , C07D495/14
Abstract: A 3-substituted 3,4,5,6,7,8-hexahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidine compound of formula IwhereinR1 is hydrogen, C1-C4-alkyl, acetyl or benzoyl, optionally substituted phenyl-C1-C4-alkyl, naphthyl-C1-C3-alkyl, phenyl-C2-C3-alkanone or a phenylcarbamoyl-C2-alkyl,R2 is optionally substituted phenyl, pyridyl, pyrimidyl or pyrazinyl, or an optionally substituted bicyclus wherein one of the two fused rings is a phenyl, a pyridyl, a pyrimidyl or a pyrazinyl ring,A is NH or oxygen,B is hydrogen or methyl,C is hydrogen, methyl or hydroxyl,X is nitrogen,Y is CH2, CH2-C2, CH2-C2-CH2 or CH2-CH,Z is nitrogen, C or CH, and the linkage between Y and Z is a single or a double bond, andn is 2, 3 or 4,or a physiologically tolerated salt thereof, and compositions comprising them and their use as antagonists of 5HT1B and 5HT1A and for the treatment of depression and related disorders.
-
公开(公告)号:CZ75999A3
公开(公告)日:1999-06-16
申请号:CZ75999
申请日:1997-08-22
Applicant: BASF AG
Inventor: STEINER GERD , LUBISCH WILFRIED , BACH ALFRED , EMLING FRANZ , WICKE KARSTEN , TESCHENDORF HANS-JURGEN , BEHL BERTHOLD , CHEETHAM SHARON , KERRRIGAN FRANK
IPC: A61K31/435 , A61K31/519 , A61P25/24 , A61P43/00 , C07D211/00 , C07D239/00 , C07D333/00 , C07D495/14
Abstract: A 3-substituted 3,4,5,6,7,8-hexahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidine compound of formula IwhereinR1 is hydrogen, C1-C4-alkyl, acetyl or benzoyl, optionally substituted phenyl-C1-C4-alkyl, naphthyl-C1-C3-alkyl, phenyl-C2-C3-alkanone or a phenylcarbamoyl-C2-alkyl,R2 is optionally substituted phenyl, pyridyl, pyrimidyl or pyrazinyl, or an optionally substituted bicyclus wherein one of the two fused rings is a phenyl, a pyridyl, a pyrimidyl or a pyrazinyl ring,A is NH or oxygen,B is hydrogen or methyl,C is hydrogen, methyl or hydroxyl,X is nitrogen,Y is CH2, CH2-C2, CH2-C2-CH2 or CH2-CH,Z is nitrogen, C or CH, and the linkage between Y and Z is a single or a double bond, andn is 2, 3 or 4,or a physiologically tolerated salt thereof, and compositions comprising them and their use as antagonists of 5HT1B and 5HT1A and for the treatment of depression and related disorders.
-
公开(公告)号:DE59505853D1
公开(公告)日:1999-06-10
申请号:DE59505853
申请日:1995-07-14
Applicant: BASF AG
Inventor: HELLENDAHL BEATE , LANSKY ANNEGRET , MUNSCHAUER RAINER , BIALOJAN SIEGFRIED , UNGER LILIANE , TESCHENDORF HANS-JUERGEN , WICKE KARSTEN , DRESCHER KARLA
IPC: C07D249/08 , A61K31/41 , A61K31/435 , A61K31/4427 , A61K31/445 , A61K31/505 , A61K31/53 , A61P1/08 , A61P25/18 , A61P25/20 , A61P25/24 , A61P25/26 , C07D249/12 , C07D249/14 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14
Abstract: PCT No. PCT/EP95/02781 Sec. 371 Date Jan. 14, 1997 Sec. 102(e) Date Jan. 14, 1997 PCT Filed Jul. 14, 1995 PCT Pub. No. WO96/02520 PCT Pub. Date Feb. 1, 1996The present invention relates to triazole compounds of the following formula: where R1, R2, A, B and Ar have the meanings stated in the description. The compounds according to the invention have a high affinity for the dopamine D3 receptor and can therefore be used to treat disorders which respond to dopamine D3 ligands.
-
27.
公开(公告)号:BG102616A
公开(公告)日:1999-04-30
申请号:BG10261698
申请日:1998-07-09
Applicant: BASF AG
Inventor: TREIBER HANS-JOERG , BLANK STEFAN , STARCK DOROTHEA , UNGER LILIANE , TESCHEDORF HANS-JUERGEN , WICKE KARSTEN
IPC: C07D243/08 , A61K31/00 , A61K31/40 , A61K31/4025 , A61K31/41 , A61K31/44 , A61K31/4427 , A61K31/4433 , A61K31/4439 , A61K31/505 , A61K31/506 , A61K31/55 , A61K31/551 , A61K31/5513 , A61P25/18 , A61P43/00 , C07D213/73 , C07D223/04 , C07D245/02 , C07D401/04 , C07D401/14 , C07D403/02 , C07D403/04 , C07D403/06 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/14 , C07D409/12 , C07D409/14 , C07D413/14 , C07D417/06 , C07D417/12 , C07D417/14
Abstract: The compounds have affinity to dopamin-D3-receptors and canbe used for the treatment of diseases caused bydopamin-D3-ligands. Aza- and diazacycloheptane and cyclooctanederivatives have the formulaAr1 - A - B - Ar2where Ar1, A, B & Ar2 have the meanings listed in the description16 claims
-
公开(公告)号:CA2307199A1
公开(公告)日:1999-04-29
申请号:CA2307199
申请日:1998-10-05
Applicant: BASF AG
Inventor: LUBISCH WILFRIED , TESCHENDORF HANS-JURGEN , GARCIA-LADONA XAVIER , WICKE KARSTEN , DULLWEBER UTA , STARCK DOROTHEA , STEINER GERD , EMLING FRANZ , BACH ALFRED
IPC: A61K31/428 , A61P25/24 , A61P43/00 , C07D275/06 , C07D417/04 , C07D417/06 , C07D417/12 , C07D417/14 , A61K31/425
Abstract: The invention relates to 2-substituted 1,2-benzisothiazole derivatives of formula (I), wherein R1 and R2 represent (C1-6) alkyl, independently of each other; A represents branched or unbranched (C1-10)-alkylene or straightchained or branched (C2-10)-alkylene comprising at least one group Z which is selected from O, S, NR7, cyclopropyl, CHOH, a double or triple bond; B represents 4-piperidine, 4-tetrahydro-1, 2, 3, 6 pyridine, 4-piperazine and the corresponding ring compounds enlarged with a methylene group, an N-atom of B providing the link with A; Ar represents phenyl which is optionally substituted by (C1-6) alkyl -branched or unbranched-, O-( C1-6)-alkyl branched or unbranched-, OH, F, Cl, Br, I, trifluoromethyl, NR5R6, CO2R7, cyano or phenyl; tetralin, indan, highly condensed aromatics such as naphthalin optionally substituted by (C1-4) alkyl or O(C1-4) alkyl; anthracene or 5- or 6-membered aromatic heterocyclene with 1 to 2 heteroatoms which are selected independently of each other from O and N and which can still be anellated with further aromatic radicals such as quinoline, isoquinoline, phthalazine, indole and quinazoline which can itself be substituted again with phenyl; and R3 and R4 have the meanings given in the description. The invention also relates to the production of the inventive derivatives and to their use as serotonin antagonists.
-
公开(公告)号:CA2296102A1
公开(公告)日:1999-01-21
申请号:CA2296102
申请日:1998-07-03
Applicant: BASF AG
Inventor: NEUMANN-SCHULTZ BARBARA , BLANK STEFAN , TESCHENDORF HANS-JUERGEN , TREIBER HANS-JOERG , STARCK DOROTHEA , LE BRIS THEOPHILE-MARIE , WICKE KARSTEN , UNGER LILIANE
IPC: A61K31/33 , A61K31/41 , A61K31/4196 , A61K31/454 , A61K31/506 , A61K31/53 , A61K31/551 , A61P25/00 , A61P25/16 , A61P25/18 , A61P25/22 , A61P25/24 , A61P43/00 , C07D249/08 , C07D249/12 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14
Abstract: The present invention relates to triazole compounds of formula (I), wherein Ar1, A, B and Ar2 have the meanings cited in the description. The inventive compounds exhibit high dopamine-D3-receptor affinity and can thus be used in the treatment of diseases responding to dopamine-D3-ligands.
-
30.
公开(公告)号:AU8535798A
公开(公告)日:1998-12-30
申请号:AU8535798
申请日:1998-05-29
Applicant: BASF AG
Inventor: STEINER GERD , DULLWEBER UTA , STARCK DOROTHEA , BACH ALFRED , WICKE KARSTEN , TESCHENDORF HANS-JURGEN , GARCIA-LADONA FRANCISCO-JAVIER , EMLING FRANZ
IPC: A61K31/505 , A61K31/519 , A61P25/00 , A61P25/24 , A61P43/00 , C07D495/14
Abstract: PCT No. PCT/EP98/03231 Sec. 371 Date Dec. 8, 1999 Sec. 102(e) Date Dec. 8, 1999 PCT Filed May 29, 1998 PCT Pub. No. WO98/56793 PCT Pub. Date Dec. 17, 19983-Substituted 3,4,5,6,7,8-hexahydropyrido [3',4':4,5]-thieno[2,3-d]pyrimidine derivatives of the formula I where R1 is a hydrogen atom, a C1-C4-alkyl group, an acetyl group, a phenylalkyl C1-C4 radical, the aromatic system being unsubstituted or substituted by halogen, C1-C4-alkyl, trifluoromethyl, hydroxyl, C1-C4-alkoxy, amino, cyano or nitro groups, or is a phenylalkanone radical, it being possible for the phenyl group to be substituted by halogen, R2 is a phenyl, pyridyl, pyrimidinyl or pyrazinyl group which is unsubstituted or mono- or disubstituted by halogen atoms, C1-C4-alkyl, trifluoromethyl, trifluoromethoxy, hydroxyl, C1-C4-alkoxy, amino, monomethylamino, dimethylamino, cyano or nitro groups and which may be fused to a benzene nucleus which can be unsubstituted or mono- or disubstituted by halogen atoms, C1-C4-alkyl, hydroxyl, trifluoromethyl, C1-C4-alkoxy, amino, cyano or nitro groups and may contain 1 nitrogen atom, or to a 5- or 6-membered ring which may contain 1-2 oxygen atoms, A is NH or an oxygen atom, Y is CH2, CH2-CH2, CH2-CH2-CH2 or CH2-CH, Z is a nitrogen atom, carbon atom or CH, it also being possible for the linkage between Y and Z to be a double bond, and n is 2, 3 or 4, and the physiologically tolerated salts thereof.
-
-
-
-
-
-
-
-
-